Loading
Life sciences · Journal article
Regenerative Therapy · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction For the wide implementation of dendritic cell-based cancer immunotherapy, a clinical phase I study was conducted to explore its safety and tolerability using Wilms’ tumor 1 (WT1) antigen-targeted human platelet lysate-induced antigen-presenting cells (WT1-HPL-APCs), developed by our team, in patients with advanced solid cancers. Methods WT1-HPL-APCs were manufactured from apheresed peripheral blood mononuclear cells administered at 4 × 10 7 cells biweekly for three sessions (one course). Adverse events and the induction of WT1-specific T cells (WT1-Cytotoxic T lymphocytes [CTLs]) were evaluated. Furthermore, the potential immunoinducibility of WT1-HPL-APC was examined in vitro and regulatory T cells and monocytic myeloid-derived suppressor cells (M-MDSCs) in the tumor microenvironment (TME) and peripheral blood were assessed to monitor immune cells. Results The adverse events associated with WT1-HPL-APC vaccination included fever, erythema at the injection site, arthralgia, and chills, all of which were lower than grade 2 in two patients who completed three sessions. The WT1 expression levels and infiltration of CD4 + T cells, CD8 + T cells, and macrophages in the TME differed among the patients. In only one of the two patients with HLA-A*24:02, WT1-HPL-APC induced WT1-CTLs in vitro. Although a WT1-CTL response could not be detected following three sessions of WT1-HPL-APC administration, the percentage of M-MDSCs in the PB tended to decrease. Conclusions As this pilot study included only three patients with different cancer types, evidence supporting the effectiveness or functionality of WT1-HPL-APCs remains limited. WT1-HPL-APC vaccination was tolerable among patients with advanced solid cancers. Our findings suggest that the immunoinducibility of WT1-HPL-APC vary across individuals and that the preexisting immunosuppressive environment could limit WT1-CTL induction. Future studies are warranted to determine whether WT1-HPL-APC vaccination can improve the patient's immunosuppressive environment and induce WT1-CTLs in combination with optimized chemotherapy or adjuvant therapy in large-scale clinical trials involving multiple doses. Clinical trial registration number jRCTc040200005.